NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY RECOVERY Study
NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY RECOVERY Study
复制标题
新生物标志物量化抗 VEGF 治疗对增生性糖尿病视网膜病变眼部超宽视野荧光血管造影的影响
DOI：
10.1097/iae.0000000000003358
复制
发表时间：
2022-03-01
影响因子：
3.3
通讯作者：
Ip, Michael
中科院分区：
文献类型：
--
作者：
Fan, Wenying;Nittala, Muneeswar Gupta;Ip, Michael
目的：定量观察增生性糖尿病视网膜病变患者注射抗血管内皮生长因子后，超宽视场荧光素血管造影立体投影图像上视网膜血管床面积（RVBA） （mm(2)）变化。方法：这是一项前瞻性观察性研究。对40只在基线和6个月后（NCT02863354）出现明显非灌注的增生性糖尿病视网膜病变患者（NCT02863354）的早期超宽视场荧光素血管造影图像（Optos 200Tx）进行立体投影，校正周围畸变。在超宽视场荧光素血管造影中提取视网膜全局血管，通过自动求和所有像素的实际尺寸（mm(2)）来计算RVBA。结果：在整个队列中，抗vegf治疗6个月后，整个视网膜的整体RVBA从67.1 +/- 15.5 mm下降到43.6 +/- 18.8 mm(2) （P < 0.001）。在每月接受抗vegf注射的亚组中，整体RVBA从68.7 +/- 16.2下降到33.9 +/- 13.3 mm(2) （P < 0.001）。在每三个月接受抗vegf治疗的亚组中，整体RVBA从65.6 +/- 15.1 mm下降到50.8 +/- 19.3 mm(2) （P = 0.004）。结论：RVBA可能是一种新的生物标志物，可以反映抗vegf注射后视网膜血管变化的效率。具有增殖性糖尿病视网膜病变和明显非灌注的眼睛在抗vegf治疗后显示RVBA减少。
Purpose: To quantify changes of the retinal vascular bed area (RVBA) in mm(2) on stereographically projected ultrawide field fluorescein angiography images in eyes with proliferative diabetic retinopathy after antivascular endothelial growth factor injection. Methods: This is a prospective, observational study. The early-phase ultrawide field fluorescein angiography images (Optos 200Tx) of 40 eyes with proliferative diabetic retinopathy and significant nonperfusion obtained at baseline and after six months (NCT02863354) were stereographically projected by correcting peripheral distortion. The global retinal vasculature on ultrawide field fluorescein angiography was extracted for calculating RVBA by summing the real size (mm(2)) of all the pixels automatically. Results: For the entire cohort, the global RVBA for the entire retina decreased from 67.1 +/- 15.5 to 43.6 +/- 18.8 mm(2) after anti-VEGF treatment at six months (P < 0.001). In the subgroup receiving monthly anti-VEGF injections, the global RVBA decreased from 68.7 +/- 16.2 to 33.9 +/- 13.3 mm(2) (P < 0.001). In the subgroup receiving anti-VEGF every three months, the global RVBA decreased from 65.6 +/- 15.1 to 50.8 +/- 19.3 mm(2) (P = 0.004). Conclusion: RVBA seems to be a new biomarker to indicate efficiency of retinal vascular changes after anti-VEGF injection. Eyes with proliferative diabetic retinopathy and significant nonperfusion demonstrate reduced RVBA after anti-VEGF treatment.